News, archive: August 2017
Between January and July 2017, Russian manufacturers produced and dispatched 176.4 bln RUB worth of pharmaceutical drugs (dispatch prices, VAT included), which is in monetary terms only 2.4% higher than that of the same period of 2016. In physical terms, the dispatch volume amounted to 2.28 bln units, which is only 0.3% higher than that of the same period of 2016.
The first half of 2017 was very vigorous for Russian pharmaceutical distributors. First, the wholesalers initiated several large, if not to say core, transactions. Representatives of Marathon Pharma announced a global partnership with Nacimbio, which is interesting in the first place for the scale of the public-private partnership. This should be a logical completion of the infrastructure of the pharmaceutical assets of Rostec. However, not every company managed to get larger, in particular, once one of the largest players of the Russian pharmaceutical wholesale Rosta sold its chain Raduga to Doktor Stoletov. While the future of Doktor Stoletov is quite obvious after the end of the integration period, the future of Rosta is rather ambiguous.
Between January and July 2017, Russia imported 329.6 bln RUB worth of pharmaceutical drugs (free circulation prices, VAT included.) Ready-made drugs account for 281.2 bln RUB, with an 8.1% increase. The in-bulk import has fallen by 24.2% (48.4 bln RUB). The total import has risen by only 1.8%.
Against rather poor growth rates in the Russian pharmaceutical retail market, chain retailers have not ceased to actively consolidate. These deals lead to the formation of new industry leaders that sweep away everything on their way to the top, or they simply strengthen the positions of certain players in local markets. The battles for the top on the country and regional levels almost do not concern market players, which are on another level. These players are still one of the main operating forces of the Russian pharmaceutical retail industry both on a regional scale (this is mostly typical for the republics of the North Caucasus), and in the market in general.
Between January and June 2017, Russia imported 302,000 units of ready-made drugs worth 376.5 mln RUB (free circulation prices) without official permission of the rightholders. Over the year, the parallel import has risen by 49% in monetary terms and by 3 times in physical terms.